# Eloxx Pharmaceuticals, Inc.: financial statements, quarterly

ELOX · Nasdaq · CIK 1035354 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/elox.md) · [Financials](/companies/elox/financials.md) · [Filings](/companies/elox/filings.md) · [Insiders](/companies/elox/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/elox/financials.md?period=annual).

## Income statement

| Line item | Unit | Q1 FY2022 (2022-03-31) | Q2 FY2022 (2022-06-30) | Q3 FY2022 (2022-09-30) | Q4 FY2022 (2022-12-31) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | period not labelled (2023-12-31) | period not labelled (2025-03-31) | period not labelled (2025-06-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating income | $m | [(11.0)](/filings/0000950170-23-021821.md) | [(10.3)](/filings/0000950170-23-041837.md) | [(7.1)](/filings/0000950170-23-062940.md) | [(6.0) d](/filings/0000950170-23-011360.md) | [(5.5)](/filings/0000950170-23-021821.md) | [(4.1)](/filings/0000950170-23-041837.md) | [(3.6)](/filings/0000950170-23-062940.md) | [(4.0) d](/filings/0001193125-26-108687.md) | [(1.2)](/filings/0001193125-26-204722.md) | [(1.6)](/filings/0001193125-26-344964.md) | [(3.8)](/filings/0001193125-26-204722.md) | [(4.5)](/filings/0001193125-26-344964.md) |
| Income tax | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net income | $m | [(11.6)](/filings/0000950170-23-062940.md) | [(10.6)](/filings/0000950170-23-062940.md) | [(7.5)](/filings/0000950170-23-062940.md) | [(6.3) d](/filings/0000950170-23-011360.md) | [(6.2)](/filings/0000950170-23-062940.md) | [(4.3)](/filings/0000950170-23-062940.md) | [(3.6)](/filings/0000950170-23-062940.md) | [(2.9) d](/filings/0001193125-26-108687.md) | [(1.7)](/filings/0001193125-26-344964.md) | [(1.9)](/filings/0001193125-26-344964.md) | [(3.8)](/filings/0001193125-26-344964.md) | [(4.5)](/filings/0001193125-26-344964.md) |
| Diluted EPS | $ per share | [(5.36)](/filings/0000950170-23-021821.md) | [(4.90)](/filings/0000950170-23-041837.md) | [(3.47)](/filings/0000950170-23-062940.md) | not reported | [(2.88)](/filings/0000950170-23-021821.md) | [(1.96)](/filings/0000950170-23-041837.md) | [(1.31)](/filings/0000950170-23-062940.md) | not reported | [(0.45)](/filings/0001193125-26-204722.md) | [(5.45)](/filings/0001193125-26-344964.md) | [(0.08)](/filings/0001193125-26-204722.md) | [(0.66)](/filings/0001193125-26-344964.md) |
| Basic EPS | $ per share | [(5.36)](/filings/0000950170-23-021821.md) | [(4.90)](/filings/0000950170-23-041837.md) | [(3.47)](/filings/0000950170-23-062940.md) | not reported | [(2.88)](/filings/0000950170-23-021821.md) | [(1.96)](/filings/0000950170-23-041837.md) | [(1.31)](/filings/0000950170-23-062940.md) | not reported | [(0.45)](/filings/0001193125-26-204722.md) | [(5.45)](/filings/0001193125-26-344964.md) | [(0.08)](/filings/0001193125-26-204722.md) | [(0.66)](/filings/0001193125-26-344964.md) |

- Revenue: not reported
- Research and development: not reported
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: not reported
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2022 (2022-09-30) | FY2022 (2022-12-31) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | period not labelled (2023-12-31) | period not labelled (2024-12-31) | period not labelled (2025-03-31) | period not labelled (2025-06-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [24.6](/filings/0000950170-23-062940.md) | [19.2](/filings/0000950170-23-062940.md) | [4.9](/filings/0000950170-23-021821.md) | [4.3](/filings/0000950170-23-041837.md) | [4.8](/filings/0000950170-23-062940.md) | [1.1](/filings/0001193125-26-108687.md) | [0.1](/filings/0001193125-26-108687.md) | [0.5](/filings/0001193125-26-204722.md) | [0.6](/filings/0001193125-26-344964.md) | [4.8](/filings/0001193125-26-344964.md) | [6.4](/filings/0001193125-26-204722.md) | [62.0](/filings/0001193125-26-344964.md) |
| Current assets | $m | [25.7](/filings/0000950170-22-024490.md) | [20.1](/filings/0000950170-23-062940.md) | [6.4](/filings/0000950170-23-021821.md) | [5.4](/filings/0000950170-23-041837.md) | [5.6](/filings/0000950170-23-062940.md) | [1.5](/filings/0001193125-26-108687.md) | [3.0](/filings/0001193125-26-108687.md) | not reported | not reported | [5.3](/filings/0001193125-26-344964.md) | [8.5](/filings/0001193125-26-204722.md) | [63.4](/filings/0001193125-26-344964.md) |
| Total assets | $m | [26.9](/filings/0000950170-22-024490.md) | [21.1](/filings/0000950170-23-062940.md) | [7.2](/filings/0000950170-23-021821.md) | [6.0](/filings/0000950170-23-041837.md) | [6.0](/filings/0000950170-23-062940.md) | [1.7](/filings/0001193125-26-108687.md) | [3.0](/filings/0001193125-26-108687.md) | not reported | not reported | [5.3](/filings/0001193125-26-344964.md) | [8.5](/filings/0001193125-26-204722.md) | [63.4](/filings/0001193125-26-344964.md) |
| Current liabilities | $m | [21.7](/filings/0000950170-22-024490.md) | [23.1](/filings/0000950170-23-062940.md) | [19.5](/filings/0000950170-23-021821.md) | [21.3](/filings/0000950170-23-041837.md) | [23.5](/filings/0000950170-23-062940.md) | [22.7](/filings/0001193125-26-108687.md) | [27.3](/filings/0001193125-26-108687.md) | not reported | not reported | [17.2](/filings/0001193125-26-344964.md) | [16.1](/filings/0001193125-26-204722.md) | [17.0](/filings/0001193125-26-344964.md) |
| Total liabilities | $m | [31.9](/filings/0000950170-22-024490.md) | [31.8](/filings/0000950170-23-062940.md) | [23.5](/filings/0000950170-23-021821.md) | [24.6](/filings/0000950170-23-041837.md) | [26.1](/filings/0000950170-23-062940.md) | [24.3](/filings/0001193125-26-108687.md) | [27.3](/filings/0001193125-26-108687.md) | not reported | not reported | [17.2](/filings/0001193125-26-108687.md) | not reported | not reported |
| Long-term debt | $m | [9.9](/filings/0000950170-22-024490.md) | [8.6](/filings/0000950170-23-062940.md) | [4.0](/filings/0000950170-23-021821.md) | [3.3](/filings/0000950170-23-041837.md) | [2.6](/filings/0000950170-23-062940.md) | [1.6](/filings/0001193125-26-108687.md) | [0.0](/filings/0001193125-26-108687.md) | not reported | not reported | [0.0](/filings/0001193125-26-108687.md) | not reported | not reported |
| Current portion of debt | $m | [2.5](/filings/0000950170-22-024490.md) | [4.0](/filings/0000950170-23-062940.md) | [1.5](/filings/0000950170-23-021821.md) | [2.3](/filings/0000950170-23-041837.md) | [2.8](/filings/0000950170-23-062940.md) | [2.2](/filings/0001193125-26-108687.md) | [6.5](/filings/0001193125-26-108687.md) | not reported | not reported | [1.0](/filings/0001193125-26-344964.md) | [0.0](/filings/0001193125-26-204722.md) | [0.0](/filings/0001193125-26-344964.md) |
| Shareholders' equity | $m | [(5.0)](/filings/0000950170-23-062940.md) | [(10.7)](/filings/0001193125-26-108687.md) | [16.3](/filings/0000950170-23-062940.md) | [(18.6)](/filings/0000950170-23-062940.md) | [(20.0)](/filings/0000950170-23-062940.md) | [(22.6)](/filings/0001193125-26-108687.md) | [(24.3)](/filings/0001193125-26-344964.md) | [(26.0)](/filings/0001193125-26-344964.md) | [(27.9)](/filings/0001193125-26-344964.md) | [(11.9)](/filings/0001193125-26-344964.md) | [(7.6)](/filings/0001193125-26-344964.md) | [46.4](/filings/0001193125-26-344964.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q1 FY2022 (2022-03-31) | Q2 FY2022 (2022-06-30) | Q3 FY2022 (2022-09-30) | Q4 FY2022 (2022-12-31) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | period not labelled (2023-12-31) | period not labelled (2025-03-31) | period not labelled (2025-06-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(9,491)](/filings/0000950170-23-021821.md) | [(9,747) d](/filings/0000950170-23-041837.md) | [(6,946) d](/filings/0000950170-23-062940.md) | [(5,661) d](/filings/0000950170-23-011360.md) | [(6,814)](/filings/0000950170-23-021821.md) | [(2,066) d](/filings/0000950170-23-041837.md) | [(3,450) d](/filings/0000950170-23-062940.md) | [(2,011) d](/filings/0001193125-26-108687.md) | [1,204](/filings/0001193125-26-204722.md) | [(1,753) d](/filings/0001193125-26-344964.md) | [(5,453)](/filings/0001193125-26-204722.md) | [(4,789) d](/filings/0001193125-26-344964.md) |
| Capital expenditure | $k | [11.0](/filings/0000950170-23-021821.md) | [7.0 d](/filings/0000950170-23-041837.md) | [48.0 d](/filings/0000950170-23-062940.md) | [0.0 d](/filings/0000950170-23-011360.md) | [0.0](/filings/0000950170-23-021821.md) | [0.0 d](/filings/0000950170-23-041837.md) | [0.0 d](/filings/0000950170-23-062940.md) | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q2 FY2021 (2021-06-30) | Q3 FY2021 (2021-09-30) | Q1 FY2022 (2022-03-31) | Q2 FY2022 (2022-06-30) | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | period not labelled (2025-03-31) | period not labelled (2025-06-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [66.4](/filings/0001564590-22-029339.md) | [86.2](/filings/0000950170-22-024490.md) | [2.2](/filings/0000950170-23-021821.md) | [2.2](/filings/0000950170-23-041837.md) | [2.2](/filings/0000950170-23-062940.md) | [2.2](/filings/0000950170-23-021821.md) | [2.2](/filings/0000950170-23-041837.md) | [2.7](/filings/0000950170-23-062940.md) | [3.8](/filings/0001193125-26-204722.md) | [0.3](/filings/0001193125-26-344964.md) | [48.2](/filings/0001193125-26-204722.md) | [6.8](/filings/0001193125-26-344964.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 4,036,459 at 2026-08-07, from the cover of the [10-Q filed 2026-08-11](/filings/0001193125-26-344964.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:31 ET. No prices; not investment advice.